PMV Pharmaceuticals (PMVP) Stock Forecast, Price Target & Predictions
PMVP Stock Forecast
PMV Pharmaceuticals stock forecast is as follows: an average price target of $24.75 (represents a 1539.07% upside from PMVP’s last price of $1.51) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
PMVP Price Target
The average price target for PMV Pharmaceuticals (PMVP) is $24.75 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $36.00 to $5.00. This represents a potential 1539.07% upside from PMVP's last price of $1.51.
PMVP Analyst Ratings
According to 4 Wall Street analysts, PMV Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for PMVP stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
PMV Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 11, 2024 | Kambiz Yazdi | Jefferies | $5.00 | $1.58 | 216.46% | 231.13% |
| Nov 17, 2022 | - | H.C. Wainwright | $36.00 | $10.29 | 249.85% | 2284.11% |
| Jun 09, 2022 | - | Oppenheimer | $33.00 | $10.24 | 222.27% | 2085.43% |
| May 24, 2022 | - | Goldman Sachs | $25.00 | $14.09 | 77.43% | 1555.63% |
The latest PMV Pharmaceuticals stock forecast, released on Apr 11, 2024 by Kambiz Yazdi from Jefferies, set a price target of $5.00, which represents a 216.46% increase from the stock price at the time of the forecast ($1.58), and a 231.13% increase from PMVP last price ($1.51).
PMV Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $5.00 |
| Last Closing Price | $1.51 | $1.51 | $1.51 |
| Upside/Downside | -100.00% | -100.00% | 231.13% |
In the current month, the average price target of PMV Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to PMV Pharmaceuticals's last price of $1.51. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 13, 2024 | Craig-Hallum | - | Buy | Initialise |
| Apr 11, 2024 | Jefferies | - | Buy | Initialise |
| Jun 09, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| May 24, 2022 | Goldman Sachs | Buy | Buy | Hold |
PMV Pharmaceuticals's last stock rating was published by Craig-Hallum on May 13, 2024. The company Initialise its PMVP rating from "null" to "Buy".
PMV Pharmaceuticals Financial Forecast
PMV Pharmaceuticals Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
PMV Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PMVP's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
PMV Pharmaceuticals EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict PMVP's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than PMV Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
PMV Pharmaceuticals Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-25.22M | $-24.71M | $-24.20M | $-24.20M | $-23.51M | $-22.31M | $-21.88M | $-20.98M | $-19.05M | $-18.09M | $-18.02M |
| High Forecast | $-25.22M | $-24.71M | $-24.20M | $-24.20M | $-23.51M | $-22.31M | $-21.88M | $-20.98M | $-19.05M | $-17.59M | $-18.02M |
| Low Forecast | $-25.22M | $-24.71M | $-24.20M | $-24.20M | $-23.51M | $-22.31M | $-21.88M | $-20.98M | $-19.05M | $-19.60M | $-18.02M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
PMV Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PMVP's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
PMV Pharmaceuticals SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
PMV Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PMVP last annual SG&A of $NaN (undefined).
PMV Pharmaceuticals EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.49 | $-0.48 | $-0.47 | $-0.47 | $-0.46 | $-0.43 | $-0.42 | $-0.41 | $-0.37 | $-0.35 | $-0.35 |
| High Forecast | $-0.49 | $-0.48 | $-0.47 | $-0.47 | $-0.46 | $-0.43 | $-0.42 | $-0.41 | $-0.37 | $-0.34 | $-0.35 |
| Low Forecast | $-0.49 | $-0.48 | $-0.47 | $-0.47 | $-0.46 | $-0.43 | $-0.42 | $-0.41 | $-0.37 | $-0.38 | $-0.35 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, PMV Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PMVP previous annual EPS of $NaN (undefined).
PMV Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.51 | $24.75 | 1539.07% | Buy |
| MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
| OPT | Opthea | $3.15 | $14.00 | 344.44% | Buy |
| PEPG | PepGen | $9.48 | $29.50 | 211.18% | Buy |
| VIGL | Vigil Neuroscience | $3.67 | $11.00 | 199.73% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| ACRV | Acrivon Therapeutics | $8.91 | $21.50 | 141.30% | Buy |
| PHVS | Pharvaris | $20.92 | $38.50 | 84.03% | Buy |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| TRDA | Entrada Therapeutics | $15.00 | $18.00 | 20.00% | Buy |
PMVP Forecast FAQ
Is PMV Pharmaceuticals a good buy?
Yes, according to 4 Wall Street analysts, PMV Pharmaceuticals (PMVP) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of PMVP's total ratings.
What is PMVP's price target?
PMV Pharmaceuticals (PMVP) average price target is $24.75 with a range of $5 to $36, implying a 1539.07% from its last price of $1.51. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will PMV Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for PMVP stock, the company can go up by 1539.07% (from the last price of $1.51 to the average price target of $24.75), up by 2284.11% based on the highest stock price target, and up by 231.13% based on the lowest stock price target.
Can PMV Pharmaceuticals stock reach $2?
PMVP's average twelve months analyst stock price target of $24.75 supports the claim that PMV Pharmaceuticals can reach $2 in the near future.
What are PMV Pharmaceuticals's analysts' financial forecasts?
PMV Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-88.672M (high $-88.672M, low $-88.672M), average SG&A $0 (high $0, low $0), and average EPS is $-1.722 (high $-1.722, low $-1.722). PMVP's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-98.324M (high $-98.324M, low $-98.324M), average SG&A $0 (high $0, low $0), and average EPS is $-1.91 (high $-1.91, low $-1.91).